
CONMED (CNMD) Stock Forecast & Price Target
CONMED (CNMD) Analyst Ratings
Bulls say
Conmed Corp demonstrated strong performance with General Surgery sales growing by 8.7% to $206.9 million, exceeding consensus estimates, while Orthopedic Surgery sales also surpassed expectations at $139.0 million, representing a 2.4% increase. The Company achieved an operating margin of 18.6%, up 280 basis points year-over-year, driven by gross margin expansion and effective operating leverage, positioning Conmed for future margin improvement. Furthermore, the gross margin reached 57.6%, slightly above expectations, indicating robust financial health despite ongoing supply chain challenges.
Bears say
Conmed Corp's financial outlook is negatively impacted by a projected slowdown in revenue growth, which is expected to fall to 4% or less due to lower-than-expected sales from key products such as AirSeal and Buffalo Filter, as well as challenges with new product launches. Additionally, management's guidance for 2025 revenue and earnings per share (EPS) is below consensus, indicating ongoing supply chain issues and potential pressure on operating margins. The company has also revised its revenue estimates downward for 2025 and 2026, reflecting a cautious stance amid risks related to hospital capital spending and adverse currency fluctuations.
This aggregate rating is based on analysts' research of CONMED and is not a guaranteed prediction by Public.com or investment advice.
CONMED (CNMD) Analyst Forecast & Price Prediction
Start investing in CONMED (CNMD)
Order type
Buy in
Order amount
Est. shares
0 shares